DIFFERENTIAL EXPRESSION OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR SUBTYPES IN CLONAL PITUITARY SOMATOTROPHS AND GONADOTROPHS

被引:104
|
作者
RAWLINGS, SR [1 ]
PIUZ, I [1 ]
SCHLEGEL, W [1 ]
BOCKAERT, J [1 ]
JOURNOT, L [1 ]
机构
[1] CNRS,INSERM,CTR PHARMACOL ENDOCRINOL,UNITE PROPRE MECANISMES MOLEC COMMUN CELLULAIRES,F-34094 MONTPELLIER 5,FRANCE
关键词
D O I
10.1210/en.136.5.2088
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) are hypothalamic factors believed to play a role in the regulation of anterior pituitary cell function. However, little is known about the expression of PACAP/VIP receptor (PVR) subtypes in such cells. Three PVR subtypes have recently been cloned: the PACAP-selective PVR1, and PVR2 and PVR3, which exhibit similar affinities for PACAP and VIP. In the present study we used the reverse transcription-polymerase chain reaction with PVR-specific primers to identify the PVR messenger RNAs (mRNAs) expressed in the somatotroph-like GH(4)C(1) and the gonadotroph-like alpha T3-1 cell lines. In parallel, the effects of PACAP and VLP on intracellular signaling were studied. GH(4)C(1) cells were found to express mRNA only for the PVR3, and neither PVR1 nor PVRS mRNA was found. PACAP and VIP stimulated Ca2+ influx responses in individual GH(4)C(1) cells and were equipotent in stimulating cAMP production (EC(50), 15 nM) in GH(4)C(1) cell populations, but failed to stimulate inositol phospholipid (PI) turnover, results consistent with the expression of a PVR3. In contrast, alpha T3-1 cells expressed mRNA for PVR1 and PVR3, but not PVR2. The predominant splice variant forms of PVR1 observed were PVR1s and PVR1hop, although the other forms (PVR1hiphop and PVR1hip) were also seen at much lower levels. PACAP stimulated a Ca2+ store-dependent Ca2+ spike and a sustained Ca2+ influx individual alpha T3-1 cells, whereas VIP only stimulated Ca2+ influx. PACAP (EC(50), similar to 3 nM) was approximately 1000-fold more potent than VIP (EC(50), similar to 3 nM) in stimulating cAMP production. PACAP also stimulated PI turnover (EC(50), similar to 20 nM), whereas VIP stimulated PI turnover only at very high (10 mu M) concentrations. These results are indicative of the expression of a PVR1. Rat anterior pituitary tissue expressed mRNAs for PVR1, PVR3, and low levels of PVR2. The coexpression of different PVRs in the same cell type and the differential expression of PVRs in different cell types would allow for a complex regulation of anterior pituitary gland function by PACAP and VIP.
引用
收藏
页码:2088 / 2098
页数:11
相关论文
共 50 条
  • [1] Special issue - Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide - Introduction
    Vaudry, Hubert
    PEPTIDES, 2007, 28 (09)
  • [2] Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland
    Vertongen, P
    Delhase, M
    Rajas, F
    Trouillas, J
    HooghePeters, E
    Svoboda, M
    Robberecht, P
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 1996, 16 (03) : 239 - 248
  • [3] PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, HELOSPECTIN, AND VASOACTIVE INTESTINAL POLYPEPTIDE IN HUMAN CORPUS CAVERNOSUM
    HEDLUND, P
    ALM, P
    EKSTROM, P
    FAHRENKRUG, J
    HANNIBAL, J
    HEDLUND, H
    LARSSON, B
    ANDERSSON, KE
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (04) : 2258 - 2266
  • [4] Pituitary adenylate cyclase-activating polypeptide
    Gonzalez, BJ
    Basille, M
    Vaudry, D
    Fournier, A
    Vaudry, H
    ANNALES D ENDOCRINOLOGIE, 1998, 59 (05) : 364 - 405
  • [5] Pituitary adenylate cyclase-activating polypeptide
    Li, XL
    Zhao, XX
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2001, 28 (02) : 140 - 144
  • [6] Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: Actions on the anterior pituitary gland
    Rawlings, SR
    Hezareh, M
    ENDOCRINE REVIEWS, 1996, 17 (01) : 4 - 29
  • [7] Effects of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide, and somatostatin on the release of thyrotropin from the bullfrog pituitary
    Okada, Reiko
    Yamamoto, Kazutoshi
    Ito, Yoichi
    Chartrel, Nicolas
    Leprince, Jerome
    Fournier, Alain
    Vaudry, Hubert
    Kikuyama, Sakae
    VIP, PACAP, AND RELATED PEPTIDES: FROM GENE TO THERAPY, 2006, 1070 : 474 - 480
  • [8] Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation
    Hashimoto, H
    Ogawa, N
    Hagihara, N
    Yamamoto, K
    Imanishi, K
    Nogi, H
    Nishino, A
    Fujita, T
    Matsuda, T
    Nagata, S
    Baba, A
    MOLECULAR PHARMACOLOGY, 1997, 52 (01) : 128 - 135
  • [9] Comparative distribution of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide immunoreactivity in the chicken forebrain
    Peeters, K
    Berghman, LR
    Vandesande, F
    TRENDS IN COMPARATIVE ENDOCRINOLOGY AND NEUROBIOLOGY: FROM MOLECULAR TO INTEGRATIVE BIOLOGY, 1998, 839 : 417 - 419
  • [10] Distribution of pituitary adenylate cyclase-activating polypeptide and pituitary adenylate cyclase-activating polypeptide type I receptor mRNA in the chicken brain
    Peeters, K
    Gerets, HHJ
    Arckens, L
    Vandesande, F
    JOURNAL OF COMPARATIVE NEUROLOGY, 2000, 423 (01) : 66 - 82